Trump will sign FDA user fee reauthorization bill, ending threat of agency layoffs
Ahead of its summer recess, the US Senate today followed its House counterparts and passed a bipartisan bill to reauthorize FDA user fee programs for prescription drugs, generic drugs, medical devices and biosimilars for the next five years. A spokesman for President Donald Trump told Focus, “The President will sign this bill, but we look forward to working with Congress to address further negotiations.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.